KING OF PRUSSIA, Pa., Dec. Www.youtobe.com 21 /PRpropagandawire/ -- CSL Behring Www.youtobe.com today announced that Helixate(R) FS, its advanced recombinant FVIII (rFVIII) Www.youtobe.com product for the treatment of hemophilia A, is now available in the Homeland in a new 2000 IU (international unit) Www.youtobe.com vial size. For patients requiring high doses of Helixate FS, the 2000 IU vial size reduces reconstitution time by eliminating the need to mix and pool multiple vials. "Helixate FS, with the new 2000 IU vial, offers patients shorter infusion times, Www.youtobe.com which translates into greater convenience, and will encourage compliance with prescribed treatment," said Robert Lefebvre, vice leader and general manager, U.S. Commercial Operations. "The introduction of the 2000 IU vial is a solid example of CSL Behring's ongoing commitment to advancing hemophilia therapy management and improving convenience for patients." Use of Helixate FS in conjunction with CSL Behring's new HeliTrax(SM) system can improve patient-physician public-relation and therapy management. The HeliTrax system combines an Internet-based encrypted database for professionals to track treatment Www.youtobe.com and a wireless hand-held electronic diary for patients to log infusions and treatments with recombinant FVIII Helixate FS. "Combining Helixate FS with HeliTrax may be ideal for the active, growing teen with hemophilia A who needs more factor product," said Jill Leone, RN, CCRP, nurse consultant. "Enhancing the system with the 2000 unit vial dosage will further improve convenience and public-relation, and enable teens to begin to manage the disease independently." Helixate FS is packaged with the Mix2Vial, an easy-to-use, plastic, needle-free transfer device with a built-in filter. Use of the Mix2Vial helps minimize the risk of injury and reduces product preparation time. For more intelligence about Helixate FS and the 2000 IU vial, please visit http://www.cslbehring.com/ or call CSL Behring Consumer Affairs at 1-888-508-6978. Helixate(R) FS is a recombinant factor VIII treatment for hemophilia A that offers convenient administration with a 2.5-mL volume diluent; no available factor VIII product has a smaller diluent size. The new 2000 vial size requires a 5.0 mL Www.youtobe.com volume diluent. Helixate(R) FS is manufactured by Bayer HealthCare LLC for CSL Behring LLC. Hemophilia is an inherited bleeding disorder characterized by prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs. About 17,000 Americans have hemophilia. The disease is caused by deficient or defective blood coagulation proteins known as factor VIII or IX. The most common form of the disease is hemophilia A, or classic hemophilia, in which the clotting factor VIII is either deficient or defective. Hemophilia B is characterized by deficient or defective factor IX. CSL Behring is a global leader in the plasma protein biotherapeutics industry. Passionate about improving the value of patients' lives, CSL Behring manufactures and sales a range of safe and effective plasma-derived and recombinant products and related services. The company's therapies are used in the treatment of immune deficiency disorders, hemophilia, von Willebrand disease, other bleeding disorders and inherited emphysema. Other products are used for the prevention of hemolytic diseases in the newborn, in cardiac surgery, organ transplantation and in the treatment of burns. The company also operates one of the world's largest plasma collection networks, ZLB Plasma. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia. For more intelligence, visit http://www.cslbehring.com/.